|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-06-11 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-01-21 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2010-09-14 |
A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins and B-cell counts in participants with NMOSD who discontinue treatment. The objectives include:
1. To establish the nadir in circulating immunoglobulins (Ig) during chronic treatment with inebilizumab and ascertain the time needed to ensure restoration of pre-treatment baseline serum levels of IgG and IgM after discontinuation of treatment
2. To characterize B-cell counts throughout treatment with inebilizumab and after discontinuation until repletion of Immunoglobulin (Ig levels)
3. To assess long-term safety of inebilizumab
4. To assess other long-term effects of inebilizumab
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren's Syndrome
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
100 项与 Horizon Therapeutics Ireland DAC 相关的临床结果
0 项与 Horizon Therapeutics Ireland DAC 相关的专利(医药)
100 项与 Horizon Therapeutics Ireland DAC 相关的药物交易
100 项与 Horizon Therapeutics Ireland DAC 相关的转化医学